On Tuesday, JAKKS Pacific, Inc. (NASDAQ:JAKK)’s shares inclined 4.12% to $8.85.
Leading U.S. toymaker JAKKS Pacific, Inc. ( JAKK) declared that based upon the unanimous approval of its independent directors, its Board of Directors has authorized the Company to purchase from time to time through March 31, 2016 up to an aggregate of $30.0 million of the Company’s outstanding common stock and/or convertible notes through open market repurchases or in privately negotiated transactions.
JAKKS Pacific, Inc. designs, develops, produces, and markets consumer products in the United States and internationally. The company’s Traditional Toys and Electronics segment offers action figures and accessories based on Batman, Star Wars, and Nintendo franchises; toy vehicles and accessories under the Road Champs, Fly Wheels, and MXS names; electronics products, such as video games under the Spy Net, Plug It In & Play TV Games, Disney, and Duck Commander brands names; fashion and baby dolls, and accessories under Disney Frozen, Disney Princess, Disney Fairies, Cabbage Patch Kids, and Graco licenses, in addition to plush, infant, and pre-school toys based on PBSs Daniel Tiger’s Neighborhood name; private label products; foot-to-floor ride-on toys, and tents and wagons based on Fisher Price, Kawasaki, and DC Comics; and pet products, counting toys, consumables, and accessories under the JAKKS Pets and American Classics brand names. Its Role Play, Novelty and Seasonal Toys segment offers role and pretend play, dress-up, and novelty products for boys and girls based on Disney Frozen, Black & Decker, McDonald’s, Dirt Devil, Disney Princess, Disney Fairies, and Dora the Explorer licenses; indoor and outdoor kids furniture, activity trays and tables, room décor, kiddie pools, and seasonal products based on Crayola and Disney names, in addition to pool floats under the Funnoodle name; Halloween and everyday costumes, and accessories under Spiderman, Iron Man, Toy Story, Sesame Street, Power Rangers, and Hasbro, Disneys Frozen, and Disney Princess brands; and balls and sport sets, and toy hoops under the Skyball, Wave Hoops, and Maui Toys brand names.
FMC Technologies, Inc. (NYSE:FTI)’s shares gained 0.43% to $42.43.
FMC Technologies, Inc. (FTI) declared the completion of the formation of a joint venture (JV) – Forsys Subsea – wherein the oilfield equipment manufacturer and Technip SA have 50% ownership each. The JV started operations from Jun 1, 2015. By combining the technology and expertise of the two subsea industry leaders, the joint venture company will be capable of assisting the upstream energy players in efficiently getting their first oil at a minimum cost.
After using Forsys Subsea’s new technology, the upstream players can enhance their profits by lowering operating costs in this weak crude pricing environment. FMC Technologies added that the newly formed company has its headquarters in London and is predictable to have a headcount of 320.
FMC Technologies added that the newly formed company has its headquarters in London and is predictable to have a headcount of 320.
Houston, TX-based FMC Technologies is a leading manufacturer and supplier of technology solutions for the energy industry. The company presently carries a Zacks Rank #3 (Hold), implying that the stock will perform in line with the broader U.S. equity market over the next one to three months.
FMC Technologies, Inc. provides technology solutions for the energy industry worldwide. The company operates through Subsea Technologies, Surface Technologies, and Energy Infrastructure segments. The Subsea Technologies segment offers subsea systems for the offshore production of crude oil and natural gas; and well access and flow administration services, counting installation and workover tools, service technicians for installation assistance, and field support services.
At the end of Tuesday’s trade, Biomed Realty Trust Inc (NYSE:BMR)‘s shares surged 0.40% to $19.92.
Biomed Realty Trust Inc (BMR) declared the completion of the sale of its property at 145 King of Prussia Road in Radnor, PA to Penn Medicine for $35 million.
This deal will allow Penn Medicine to develop its own plan for the site in partnership with the Radnor Township. The transaction will result in an approximate $32 million impairment loss, which the company will record in the second quarter.
BioMed Realty Trust, Inc. operates as a real estate investment trust (REIT) that focuses on providing real estate to the life science industry in the United States. Its tenants primarily comprise biotechnology and pharmaceutical companies, scientific research institutions, government agencies, and other entities involved in the life science industry. \
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), ended its Tuesday’s trading session showed no change, and closed at $8.55.
Ariad Pharmaceuticals, Inc. (ARIA) and Paladin Labs Inc., an operating company of Endo International plc (ENDP) (ENL.TO), recently declared that ARIAD has granted Paladin exclusive rights to distribute Iclusig™ (as ponatinib hydrochloride) in Canada for its newly approved indications. Paladin is focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market.
Health Canada approved Iclusig for the treatment of adult patients with all phases of chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) for whom other tyrosine kinase inhibitor (TKI) therapy is not appropriate, counting CML or Ph+ ALL that is T315I mutation positive, or where there is prior TKI resistance or intolerance. Iclusig will be made accessible through a controlled distribution program, whereby prescribers who have accomplished the certification procedure will be able to prescribe Iclusig.
ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, Europe, and other territories.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
